“…With the exception of the Bm86 antigen, directed against R. microplus, already included in a commercial vaccine (Canales et al, 2009;Rodriguez et al, 1994;Willadsen, 2006;Willadsen et al, 1989), identification of efficient antigens is still a major limitation in the development of new vaccines (Parizi et al, 2012) stressing the need for new experimental approaches or the combination of different approaches to develop effective vaccines (de la Fuente and . A low cost alternative for testing new compounds directed to tick inoculation of medicines or antibodies against a specific protein, while not completely abolishing the need of cattle use, would significantly reduce it (Gonsioroski et al, 2012;LewTabor et al, 2014). One approach to increase the possibilities of identifying tick protective antigens is to combine RNAi functional studies with in vitro tick feeding.…”